Rubin On Point | Rethinking Recovery | Hamilton Baiden

Rubin On Point | Patient Perspectives; She learned Who She Really Was| Miclayn McCready

What happens when life forces you to rebuild everything—your health, your identity, your relationships, and your future?In this deeply personal Patient Perspectives episode of Rubin On Point, Dr. Dan Rubin sits down with Micalyn McCready to unpack her extraordinary journey through tongue cancer, lung metastasis, brain lesions, radiation, immunotherapy, infections, seizures, and ultimately… remission.Micalyn shares what it was like to undergo tongue reconstruction surgery, relearn speech, navigate years of treatment, and completely reevaluate who and what truly mattered in her life. From losing friendships to discovering resilience, environmental health, and self-advocacy, this episode is an honest conversation about survival—and the mindset that carried her through it all.This is not just a cancer story.It’s a story about identity, perspective, and becoming stronger through unimaginable adversity.Topics Covered:* Tongue cancer diagnosis & reconstruction surgery* Living with an “arm tongue”* Radiation & immunotherapy treatment* Brain lesions, seizures, and hospitalizations* The emotional reality of survivorship* Friendships, support systems & boundaries* Environmental toxins, PFAS & heavy metals* Mindset, resilience & rebuilding life after cancerChapters:00:00 – Introduction01:05 – Meeting Micalyn & her diagnosis03:20 – Discovering tongue cancer10:37 – Life after tongue reconstruction surgery14:24 – Radiation treatment & recovery16:34 – Lung metastasis & immunotherapy21:28 – How cancer changed relationships25:05 – Redefining priorities & identity29:14 – Brain lesions & seizures36:02 – Severe infections & complications41:12 – Environmental toxins & PFAS discussion44:26 – Living cancer free

Rubin On Point | Decoding Dendritic Cell Therapy: Turning Tumors Into Targets | Rafael Gonzalez PhD

What if your immune system already knows how to fight cancer… it just needs the right instructions? In this episode of Rubin On Point, Dr. Dan Rubin sits down with Rafael Gonzalez, regenerative medicine expert and Lead Scientific Advisor for Immunocine, to unpack one of the most advanced frontiers in oncology: dendritic cell therapy. Immunocine is focused on personalized dendritic cell immunotherapy—using an individual’s own tumor biology to help train the immune system to  recognize and target cancer with precision. This conversation breaks down how cellular therapies are shifting oncology toward personalization, immune intelligence, and biologically driven treatment strategies. Together, they explore: • Why dendritic cells are considered the “command center” of the immune system • The difference between immune stimulation vs. true immune targeting • How natural killer (NK) cells help eliminate damaged and aging cells • The role of exosomes and cellular communication in healing and disease • Why preserving tumor tissue may become a critical part of future cancer care They also discuss Immunocine Preserve, a tumor tissue preservation program designed to store biopsy or surgical tumor samples for potential future use in personalized immunotherapy and emerging cellular therapies. Because many biopsies are not preserved correctly for future immune-based treatments, this process gives people the opportunity to preserve valuable tumor biology before it’s lost. This is a deep, honest conversation about where oncology, immunology, and regenerative medicine are heading next—and what it means for people navigating a cancer diagnosis today. 🔗 Learn more about Immunocine: Immunocine.com 🔗 Learn more about Immunocine Preserve: ImmunocinePreserve.com #RubinOnPoint #Immunotherapy #DendriticCellTherapy #IntegrativeOncology #CancerCare #PrecisionMedicine #ImmuneHealth ⏱ Chapters 00:00 – Intro: Cancer, resilience, and being human 01:03 – Who is Dr. Rafael Gonzalez? 02:42 – What “vaccine” really means in immunology 08:15 – What is dendritic cell therapy? 10:02 – How tumors are used to train the immune system 12:53 – Why tumor preservation matters (Immunocine Preserve) 17:06 – Why most biopsies can’t be used later 19:09 – How the treatment process works 22:49 – Natural killer (NK) cells explained 23:19 – What are “zombie cells” (senescence)? 26:33 – Anti-aging + immune system connection 28:30 – Engineering NK cells for therapy 35:56 – What are exosomes (and why they matter)? 41:06 – Risks in the exosome space 44:18 – Why NK cells may be the future 47:10 – Final thoughts on cellular therapy

Rubin On Point | Rethinking Recovery | Hamilton Baiden

Rewriting Recovery: A Human-First Approach to Addiction & Mental Health What if the biggest problem in addiction recovery… is the way we treat it? In this powerful episode of Rubin On Point, Dr. Dan Rubin sits down with Hamilton Baiden, CEO & Founder of YouTurn Health, to challenge everything we think we know about behavioral health, substance use, and recovery. Hamilton shares his deeply personal journey—from a high-functioning executive battling addiction to building a nationwide virtual platform designed to close the gaps traditional treatment leaves behind. This conversation goes beyond addiction—it’s about human connection, stigma, family impact, and why most people never get help in the first place. If you’ve ever struggled—or loved someone who has—this episode is for you. ⏱️ Chapters 00:00 – Introduction to Rubin On Point 00:42 – Meet Hamilton Baiden & YouTurn Health 01:39 – Addiction from the inside: “I was a normal guy” 04:04 – The moment everything changed (getting sober) 06:01 – The real problem with traditional treatment 06:38 – Why 90% of people never ask for help 07:56 – The forgotten victims: family members 09:21 – The shocking truth about treatment adherence 10:38 – Building a system that actually works 12:33 – Why “just quit” doesn’t work 14:02 – Human-first care vs. institutional models 16:15 – Why virtual support is more effective than you think 17:23 – The power of real-time connection 18:42 – Supporting families through addiction 20:02 – Meeting people where they are (not where we want them to be) 22:01 – Mental health vs. substance use: what’s different? 24:30 – “Netflix for behavioral health” explained 26:33 – Why people don’t want therapy—but still need help 27:10 – Stress, anxiety, and long-term health consequences 28:15 – The family perspective: healing both sides 30:25 – Neurobiology of addiction explained 32:05 – Psychedelics, research, and future treatment 34:21 – Social media, dopamine & rising anxiety 36:09 – What addiction actually looks like day-to-day 38:14 – The emotional toll: anxiety, depression, and memory gaps 39:36 – The truth about sobriety (no clichés) 41:25 – Redefining recovery: does everyone need to quit? 43:06 – Can people learn to drink responsibly? 44:17 – Why one-size-fits-all treatment fails 44:35 – Final thoughts: changing the future of recovery

Rubin On Point | Epigenomics in Cancer: Understanding Tumor Signals | Brandon Guida PhD

Cancer isn’t just about mutations. In Part 2 of this conversation, Dr. Brandon Guida breaks down how epigenomics is transforming the way we detect, monitor, and understand cancer in real time. If Part 1 explained the “operating system,” this episode shows how that system becomes a fingerprint for disease—and how we can actually measure it. We dive into: * How epigenomic patterns create a detectable cancer signature * The difference between ctDNA vs cfDNA * Why methylation increases sensitivity in cancer detection * How tumors evolve (and why treatment can stop working) * What tumor fraction really means—and why it matters * The clinical gap: why this data isn’t used enough (yet) This is where diagnostics meet precision medicine. And where the future of oncology is heading. ⏱️ CHAPTERS 00:00 – Welcome back + Part 1 recap 00:52 – Epigenomics in cancer: what changes 53:31 – Cancer “fingerprints” explained 54:29 – Multi-cancer early detection tests 55:14 – ctDNA vs cfDNA (the “haystack” analogy) 57:20 – The future: multi-modal diagnostics 58:04 – Why epigenomics improves detection sensitivity 01:00:11 – Mutations vs epigenetic changes 01:01:20 – Why methylation gives more signal 01:02:32 – BRCA: mutation vs epigenetic silencing 01:04:09 – Why testing matters (if you’re looking for it) 01:07:18 – Tp53 explained (and why it’s a big deal) 01:13:58 – Clonal evolution + treatment resistance 01:15:50 – Tumor fraction: how it’s calculated 01:16:52 – When treatment looks like it’s working—but isn’t 01:18:10 – Why clinicians aren’t using this enough (yet)

Rubin On Point | Epigenomics 101: The Missing Layer of Medicine | Brandon Guida, PhD

What if your DNA isn’t your destiny? In Part 1 of this conversation, Dr. Dan Rubin sits down with molecular diagnostics expert Dr. Brandon Guida to break down epigenomics—the system that controls how your genes are actually expressed. This is the layer above your DNA… the one that decides what gets turned on, turned off, and when. If genetics are the blueprint, epigenomics is the operating system. And it’s constantly changing. In this episode, we unpack: * What epigenomics actually is (without the jargon) * Why DNA methylation is only part of the story * The difference between genetic testing vs. epigenetic insight * How lifestyle, environment, and exposures shape your biology * Why two people with the same genes can have completely different outcomes This is foundational. And it sets the stage for how we think about cancer, resilience, and personalized medicine. ⏱️ CHAPTERS 00:00 – Welcome to Rubin On Point 00:42 – Introducing Dr. Brandon Guida 01:23 – What is epigenomics (really)? 02:23 – Why DNA methylation is oversimplified 03:17 – MTHFR vs. epigenomics (key distinction) 05:04 – Genotype vs. phenotype explained 06:30 – The origin of epigenetics (Waddington’s model) 09:07 – How methylation actually turns genes on/off 10:31 – The “iPhone” analogy for your biology 13:42 – Genes vs. epigenome: who’s in control? 14:59 – Can your epigenome be changed? 18:02 – Epigenetic “memory” and environmental impact 19:55 – What happens in cancer (epigenetically) 22:28 – Tumor suppressor genes + methylation 23:41 – Why this matters clinically (Part 2 preview)